KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Arbutus Biopharma (ABUS) EPS (Basic) (2016 - 2025)

Arbutus Biopharma's EPS (Basic) history spans 13 years, with the latest figure at -$0.04 for Q3 2025.

  • For Q3 2025, EPS (Basic) rose 60.0% year-over-year to -$0.04; the TTM value through Sep 2025 reached -$0.23, up 46.51%, while the annual FY2024 figure was -$0.38, 13.64% up from the prior year.
  • EPS (Basic) for Q3 2025 was -$0.04 at Arbutus Biopharma, down from $0.01 in the prior quarter.
  • Across five years, EPS (Basic) topped out at $0.01 in Q2 2025 and bottomed at -$0.24 in Q3 2021.
  • The 5-year median for EPS (Basic) is -$0.11 (2022), against an average of -$0.12.
  • The largest YoY upside for EPS (Basic) was 109.09% in 2025 against a maximum downside of 30.0% in 2025.
  • A 5-year view of EPS (Basic) shows it stood at -$0.15 in 2021, then rose by 6.67% to -$0.14 in 2022, then grew by 14.29% to -$0.12 in 2023, then surged by 41.67% to -$0.07 in 2024, then soared by 42.86% to -$0.04 in 2025.
  • Per Business Quant, the three most recent readings for ABUS's EPS (Basic) are -$0.04 (Q3 2025), $0.01 (Q2 2025), and -$0.13 (Q1 2025).